Your browser doesn't support javascript.
loading
Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.
Savelkoul, Edo H J; Thomas, Pepijn W A; Derikx, Lauranne A A P; den Broeder, Nathan; Römkens, Tessa E H; Hoentjen, Frank.
Afiliação
  • Savelkoul EHJ; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Thomas PWA; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Derikx LAAP; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • den Broeder N; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Römkens TEH; Department of Gastroenterology and Hepatology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, the Netherlands.
  • Hoentjen F; Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Inflamm Bowel Dis ; 29(10): 1633-1647, 2023 10 03.
Article em En | MEDLINE | ID: mdl-36318229
Annual loss of response in ulcerative colitis was 10% for infliximab and 13% for adalimumab, with higher rates during the first year. Annual dose escalation was higher than loss of response, with clinical benefit for 72% (infliximab) and 52% (adalimumab).
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Idioma: En Ano de publicação: 2023 Tipo de documento: Article